Authors/Disclosures
|
Omar A. Khan, MD, PhD
(Dept of Neuro/Wayne State Univ Sch of Med)
|
No disclosure on file |
|
Jai Perumal, MD
|
Dr. Perumal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Perumal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for T G therapeutics. Dr. Perumal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. |
|
|
No disclosure on file |
|
Christina Caon, RN, BS
(38 North Street)
|
Ms. Caon has received personal compensation for serving as an employee of EMD Serono. |
|
Fen Bao
|
Fen Bao has nothing to disclose. |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Alexandros C. Tselis, MD, PhD
(WSU Sch of Med/Dept of Neur Health Ctr)
|
No disclosure on file |
|
|
No disclosure on file |
|
Bruce A. Cree, MD, PhD, MAS, FAAN
(UCSF, Multiple Sclerosis Center)
|
The institution of Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neuron23. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Pharma. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hexal/Sandoz. Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic AG. The institution of Dr. Cree has received research support from Genentech. The institution of Dr. Cree has received research support from Kyverna. Dr. Cree has received publishing royalties from a publication relating to health care. |
|
Jorge Oksenberg, MD
(UCSF)
|
No disclosure on file |
|
Stephen L. Hauser, MD
(UCSF Weill Institute for Neurosciences)
|
Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NGM Bio. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BD. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pheno Therapeutics. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nurix Therapeutics. Dr. Hauser has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gilead. Dr. Hauser has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Accure. Dr. Hauser has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alector. Dr. Hauser has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hinge Therapeutics. Dr. Hauser has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Neurona. Dr. Hauser has a non-compensated relationship as a Clinical Trial/Primary Investigator with Roche that is relevant to AAN interests or activities. Dr. Hauser has a non-compensated relationship as a Clinical Trial/Primary Investigator with Novartis that is relevant to AAN interests or activities. |
|
|
No disclosure on file |